Nonhuman primate models of islet transplantation: Preclinical testing of novel immunotherapies

Research output: Contribution to journalArticle

Abstract

Studies in rodent models provide key insights into the pathways that regulate immune responses to foreign antigens, including transplanted tissues. In addition, spontaneous and induced models of autoimmunity in these species allow for dissection of cellular and molecular routes to disease, translation of the results to larger animal models (e.g., nonhuman primates) and humans, however, is rarely straightforward. Clinically islet cell transplantation has resulted in reversal of hyperglycemia and normalization of metabolic control, without the occurrence of hypoglycemia, in a limited number of patients. The immunosuppressive agents that work well for solid organ transplantation only rarely lead to insulin independence and long-term islet allograft survival. The reasons for this disappointing success rate include rejection, recurrence of autoimmunity early islet loss as a consequence of nonspecific inflammatory events that occur upon intrahepatic islet transplantation, and the adverse effects of conventional immunosuppressive drugs on islet cell function. The introduction of novel immunomodulatory agents has, for the first time, recently led to advances in our ability to consistently prevent rejection and allow for long-term insulin independence in nonhuman primates.

Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalDiabetes Reviews
Volume7
Issue number3
StatePublished - Jan 1 1999

Fingerprint

Islets of Langerhans Transplantation
Immunosuppressive Agents
Autoimmunity
Islets of Langerhans
Immunotherapy
Primates
Insulin
Cell Transplantation
Organ Transplantation
Hypoglycemia
Hyperglycemia
Allografts
Dissection
Rodentia
Animal Models
Antigens
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Nonhuman primate models of islet transplantation : Preclinical testing of novel immunotherapies. / Kenyon, Norma S; Kenyon, N. M.; Ricordi, Camillo.

In: Diabetes Reviews, Vol. 7, No. 3, 01.01.1999, p. 183-186.

Research output: Contribution to journalArticle

@article{c1bb69cf4fcb4ad0b24ab90a9dc18054,
title = "Nonhuman primate models of islet transplantation: Preclinical testing of novel immunotherapies",
abstract = "Studies in rodent models provide key insights into the pathways that regulate immune responses to foreign antigens, including transplanted tissues. In addition, spontaneous and induced models of autoimmunity in these species allow for dissection of cellular and molecular routes to disease, translation of the results to larger animal models (e.g., nonhuman primates) and humans, however, is rarely straightforward. Clinically islet cell transplantation has resulted in reversal of hyperglycemia and normalization of metabolic control, without the occurrence of hypoglycemia, in a limited number of patients. The immunosuppressive agents that work well for solid organ transplantation only rarely lead to insulin independence and long-term islet allograft survival. The reasons for this disappointing success rate include rejection, recurrence of autoimmunity early islet loss as a consequence of nonspecific inflammatory events that occur upon intrahepatic islet transplantation, and the adverse effects of conventional immunosuppressive drugs on islet cell function. The introduction of novel immunomodulatory agents has, for the first time, recently led to advances in our ability to consistently prevent rejection and allow for long-term insulin independence in nonhuman primates.",
author = "Kenyon, {Norma S} and Kenyon, {N. M.} and Camillo Ricordi",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "183--186",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Nonhuman primate models of islet transplantation

T2 - Preclinical testing of novel immunotherapies

AU - Kenyon, Norma S

AU - Kenyon, N. M.

AU - Ricordi, Camillo

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Studies in rodent models provide key insights into the pathways that regulate immune responses to foreign antigens, including transplanted tissues. In addition, spontaneous and induced models of autoimmunity in these species allow for dissection of cellular and molecular routes to disease, translation of the results to larger animal models (e.g., nonhuman primates) and humans, however, is rarely straightforward. Clinically islet cell transplantation has resulted in reversal of hyperglycemia and normalization of metabolic control, without the occurrence of hypoglycemia, in a limited number of patients. The immunosuppressive agents that work well for solid organ transplantation only rarely lead to insulin independence and long-term islet allograft survival. The reasons for this disappointing success rate include rejection, recurrence of autoimmunity early islet loss as a consequence of nonspecific inflammatory events that occur upon intrahepatic islet transplantation, and the adverse effects of conventional immunosuppressive drugs on islet cell function. The introduction of novel immunomodulatory agents has, for the first time, recently led to advances in our ability to consistently prevent rejection and allow for long-term insulin independence in nonhuman primates.

AB - Studies in rodent models provide key insights into the pathways that regulate immune responses to foreign antigens, including transplanted tissues. In addition, spontaneous and induced models of autoimmunity in these species allow for dissection of cellular and molecular routes to disease, translation of the results to larger animal models (e.g., nonhuman primates) and humans, however, is rarely straightforward. Clinically islet cell transplantation has resulted in reversal of hyperglycemia and normalization of metabolic control, without the occurrence of hypoglycemia, in a limited number of patients. The immunosuppressive agents that work well for solid organ transplantation only rarely lead to insulin independence and long-term islet allograft survival. The reasons for this disappointing success rate include rejection, recurrence of autoimmunity early islet loss as a consequence of nonspecific inflammatory events that occur upon intrahepatic islet transplantation, and the adverse effects of conventional immunosuppressive drugs on islet cell function. The introduction of novel immunomodulatory agents has, for the first time, recently led to advances in our ability to consistently prevent rejection and allow for long-term insulin independence in nonhuman primates.

UR - http://www.scopus.com/inward/record.url?scp=0032742976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032742976&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032742976

VL - 7

SP - 183

EP - 186

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -